The Phase Ib/II clinical study of IMM01 combined with PD-1 antibody in the treatment of relapsed and refractory malignant tumors completed the first patient enrollment and administration

On May 17, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") announced the FPI in the Phase Ib/II clinical study of first domestic SIRPα-Fc fusion protein targeting human CD47 (project number: IMM01) combin......

2022-05-17

ImmuneOnco was invited to give an oral presentation at the PEGS Boston Summit

In May 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") was invited to participate in the PEGS Boston Summit held in Boston, USA. Dr. Tian Wenzhi, founder, chairman and CEO of ImmuneOnco, authorized Dr. Zh......

2022-05-10

ImmuneOnco Announced Appointment of Dr. Xiaodong Gan as Senior Vice President for Clinical trials

On April 1, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") announced the appointment of Dr. Frank Xiaodong Gan was appointed as the senior vice president of our Company in April 2022, and is responsible fo......

2022-04-01

ImmuneOnco Announced Appointment of Dr. Xu, Wencheng as Vice President of Clinical Operations

On March 30, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") announced the appointment of Dr. Xu, Wencheng as the vice president of clinical operations. After graduating from the Departmen......

2022-03-30

Invention patent of IMM0306 was authorized by the US Patent Office

On March 29, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") declared that the bispecific antibody drug targeting both CD47 and CD20 (Project No.: IMM0306) was authorized by the US Patent Office (APPLICAT......

2022-03-29